drugset / Trial / NCT02790034

Evaluation of the Efficacy, Safety, and Tolerability of Sarizotan in Rett Syndrome With Respiratory Symptoms

NCT02790034

Phase 2/3 Terminated 129 enrolled Newron Pharmaceuticals SPA
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This study evaluates the safety, tolerability and efficacy of Sarizotan in reducing respiratory abnormalities in Rett Syndrome in an initial double blind 24 week period followed by an open label treatment phase of up to 168 weeks (the latter for patients with no safety and tolerability issues).

Timeline

Start
2016-10-26
Primary completion
2019-08-06
Completion
2020-05-04

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Sarizotan Small molecule 2 mg
Subject Sarizotan Small molecule 5 mg
Subject Sarizotan Small molecule 10 mg

Indications